Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of Cotadutide in chronic kidney disease with type 2 diabetes mellitus
jRCT2031200187Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2021
- Modality
- Peptides
01
Overview
Phase 2, randomised, double-blind trial of cotadutide in chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM) and diabetic glomerulosclerosis (5 arms), sponsored by AstraZeneca. Primary endpoints: Change and percentage change in UACR from baseline to week 14 and Rate of change in UACR from baseline to week 14. Started Jan 2021; status: completed.
02
Drugs
cotadutide
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosis
Beyond the preview
Go deeper on jRCT2031200187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200187.